- Home
- CCIF vs IMA Comparison
CCIF vs IMA Comparison
Compare CCIF & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCIF | IMA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 54.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CCIF | IMA |
|---|---|---|
| Price | $3.19 | $5.42 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 124.6K | 56.8K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.01 | $3.94 |
| 52 Week High | $6.61 | $17.50 |
Technical Indicators
Market Signals| Indicator | CCIF | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 48.97 |
| Support Level | $3.01 | $5.23 |
| Resistance Level | $3.45 | $7.17 |
| Average True Range (ATR) | 0.10 | 0.37 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 4.87 | 49.50 |
Price Performance
Historical ComparisonAbout CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.